Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02791334 · ClinicalTrials.gov registry record · Phase 1
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
A Phase 1 study of Pancreatic Cancer and Solid Tumor, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 164
- Enrollment target
- 14
- Study locations
NCT02791334 is a Phase 1 study of Pancreatic Cancer and Solid Tumor that has completed, run by Eli Lilly and Company. The registered enrollment target is 164 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (58% lower). The trial reports 14 study locations across 4 states.
The verdict
NCT02791334, a Phase 1 study of Pancreatic Cancer and Solid Tumor, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 164 participants
- Enrollment target
- 14
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.
Conditions Studied
Interventions
- DRUG Abemaciclib
- DRUG Ramucirumab
- DRUG Merestinib
- DRUG LY3300054
- DRUG LY3321367
Study Locations (14)
Other
- Cliniques Universitaires Saint-Luc - Brussels
- Universitair Ziekenhuis Antwerpen - Edegem
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest - Bordeaux
- Gustave Roussy - Villejuif
- Seoul National University Hospital - Seoul
- Severance Hospital Yonsei University Health System - Seoul
- Hospital Universitario Fundación Jiménez Díaz - Madrid
- Hospital Madrid Norte Sanchinarro - Madrid
- National Cheng Kung University Hospital - Tainan
- National Taiwan University Hospital - Taipei
Texas
- University of Texas MD Anderson Cancer Center - Houston
- The START Center for Cancer Care - San Antonio
Tennessee
- Tennessee Oncology PLLC - Nashville
Ontario
- Princess Margaret Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2016-06-29 |
| Est. Completion | 2024-06-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02791334
The ClinicalTrials.gov registry entry for NCT02791334 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (58% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 5 interventions - of which Abemaciclib is the first listed.
NCT02791334 reports 14 study locations spanning 4 distinct geographic areas - top geographies include Other, Texas, Tennessee.
Frequently Asked Questions
What is clinical trial NCT02791334 about?
NCT02791334 is a clinical study titled "A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors". The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.
What is the current status of trial NCT02791334?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 164 participants. The study started on 2016-06-29. Estimated completion is 2024-06-27.
What conditions does trial NCT02791334 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Solid Tumor, Cutaneous Melanoma, Microsatellite Instability-High (MSI-H) Solid Tumors, Breast Cancer (HR+HER2-).
What interventions are being tested in trial NCT02791334?
The interventions under investigation include: Abemaciclib (DRUG), Ramucirumab (DRUG), Merestinib (DRUG), LY3300054 (DRUG), LY3321367 (DRUG).
Who is sponsoring clinical trial NCT02791334?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02791334 being conducted?
This trial has 14 study locations across Tennessee, Texas, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.